Sub-Clinical Atrial Fibrillation Biomarker Study

NCT02840201

Last updated date
Study Location
University of Ottawa Heart Institute
Ottawa, Ontario, K1Y 4W7, Canada
Contact
613-696-7000

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

613-696-7000

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Subclinical Atrial Fibrillation
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
55 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Permanent pacemaker or defibrillator (with or without resynchronization) or insertable cardiac monitor

- At least one episode of device-detected SCAF ≥ 6 minutes in duration but no single episode > 24 hours in duration at any time prior to enrollment. Any atrial high rate episode with average > 175 beats/min will be considered as SCAF. No distinction will be made between atrial fibrillation and atrial flutter. SCAF requires electrogram confirmation (at least one episode) unless ≥ 6 hours in duration

- Age ≥ 55 years

- Risk Factor(s) for Stroke:

Previous stroke, TIA or systemic arterial embolism OR Age at least 75 OR Age 65-74 with at least 2 other risk factors OR Age 55-64 with at least 3 other risk factors

Other risk factors are:

- Hypertension

- CHF

- Diabetes

- Vascular disease (i.e. CAD, PAD or Aortic Plaque)

- Female

- Must be from a participating Canadian recruitment centre

- Consent to participate in the ARTESiA parent study

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Clinical atrial fibrillation documented by surface ECG (12 lead ECG, Telemetry,
Holter) lasting ≥ 6 minutes, with or without clinical symptoms


- Mechanical valve prosthesis, recent (within past 6 months) deep vein thrombosis or
pulmonary embolism or other condition requiring treatment with an anticoagulant


- Allergy to aspirin or apixaban


- Severe renal insufficiency (serum creatinine > 2.5 mg/dL [221 μmol/L] or a calculated
creatinine clearance < 25 ml/min)


- Serious bleeding in the last 6 months or at high risk of bleeding (this includes, but
is not limited to: prior intracranial hemorrhage, active peptic ulcer disease,
clinically significant thrombocytopenia or anemia, recent stroke within past 10 days,
documented hemorrhagic tendencies or blood dyscrasias)


- Moderate to severe hepatic impairment


- Ongoing need for combination therapy with aspirin and clopidogrel (or other
combination of two platelet inhibitors)


- Meets criteria for requiring lower dose of apixaban AND also has ongoing need for
strong inhibitors of both CYP3A4 and P-glycoprotein (e.g., ketoconazole, itraconazole,
ritonavir or clarithromycin)


- Ongoing need for strong inducers of both CYP3A4 and P-glycoprotein (e.g., rifampin,
carbamazepine, phenytoin, St. John's wort)


- Received an investigational drug in the past 30 days


- Participants considered by the investigator to be unsuitable for the study for any of
the following reasons:


- Not agreeable for treatment with either aspirin or apixaban or anticipated to have
poor compliance on study drug treatment


- Unwilling to attend study follow-up visits


- Life expectancy less than 2 years due to concomitant disease


- Women who are pregnant, breast-feeding or of child-bearing potential without an
acceptable form of contraception in place (sterilization, abstinence or other method
with less than 1% failure rate)

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Subclinical Atrial FibrillationSub-Clinical Atrial Fibrillation Biomarker Study
NCT02840201
  1. Ottawa, Ontario
ALL GENDERS
55 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title Sub-Clinical Atrial Fibrillation Biomarker Study
Official Title Sub-Clinical Atrial Fibrillation Biomarker (SCAF-b): A Sub-study of Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA)
Brief Summary This is a sub-study of the ARTESiA study registered as NCT01938248. This study is designed to validate biomarkers in subclinical atrial fibrillation and to determine if the prospective biomarker will be informative of the potential efficacy of treatment.
Detailed Description

Atrial fibrillation (AF) is the most common cardiac rhythm disorder worldwide, and is gaining in prevalence. Currently, the treatment for atrial fibrillation is concentrated on patients with existing atrial fibrillation, and the reduction in risks of complications of stroke with anticoagulation. Furthermore, mechanical interventions such as atrial ablation procedures are fraught with inconsistent results. The availability of serum based biomarkers that can predict the early onset of atrial fibrillation, and also the ability to prognosticate risk, may help in the identification of patients at risk for AF complications early. This would also allow the identification of the patient population most suitable for the evaluation of possible future intervention strategies to prevent the onset of atrial fibrillation, and alter its natural history and complications.

Currently the best biomarkers in predicting atrial fibrillation risk are in fact markers for heart failure - NTproBNP and high sensitivity troponin. These markers are independent from CHA2DS2-VASc score. While this is very helpful, these markers will not be able to distinguish these 2 conditions because heart failure and atrial fibrillation often co-exist. The investigator's Cardiovascular Biomarker Discovery and Translation team has been using deep proteomic analysis of both human tissues and reprogrammed human stem cells to identify novel candidate biomarkers. This has been very successfully applied to diastolic heart failure, and there are now several new markers for this condition that have been validated across 3 populations. The investigators have several potential candidates for atrial fibrillation, but validation in the appropriate cohort, particularly those at the earliest risks of atrial fibrillation, will be most important.

The ARTESiA study is an ideal study setting to perform the biomarker validation, as the parent trial will recruit patients with silent atrial fibrillation detected only by dual-chamber pacemakers, defibrillators or insertable cardiac monitors. This would constitute a potentially earlier stage atrial fibrillation patient cohort, with known subsequent risks in a prospective fashion. The prospective evaluation of approved medications of aspirin and apixaban will also be helpful to determine if the prospective biomarker will be informative of the potential efficacy of treatment, or be unchanged by the treatment modalities.

Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Retention:   Samples Without DNA
Description:
Blood samples will be collected for biomarker evaluation.
Sampling Method Probability Sample
Study Population Canadian patients participating in the ARTESiA study will be recruited for this sub-study.
Condition Subclinical Atrial Fibrillation
Intervention Not Provided
Study Groups/Cohorts Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Recruiting
Estimated Enrollment
 (submitted: July 18, 2016)
700
Original Estimated Enrollment Same as current
Estimated Study Completion Date July 2021
Estimated Primary Completion Date August 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Permanent pacemaker or defibrillator (with or without resynchronization) or insertable cardiac monitor
  • At least one episode of device-detected SCAF ? 6 minutes in duration but no single episode > 24 hours in duration at any time prior to enrollment. Any atrial high rate episode with average > 175 beats/min will be considered as SCAF. No distinction will be made between atrial fibrillation and atrial flutter. SCAF requires electrogram confirmation (at least one episode) unless ? 6 hours in duration
  • Age ? 55 years
  • Risk Factor(s) for Stroke:

Previous stroke, TIA or systemic arterial embolism OR Age at least 75 OR Age 65-74 with at least 2 other risk factors OR Age 55-64 with at least 3 other risk factors

Other risk factors are:

  • Hypertension
  • CHF
  • Diabetes
  • Vascular disease (i.e. CAD, PAD or Aortic Plaque)
  • Female
  • Must be from a participating Canadian recruitment centre
  • Consent to participate in the ARTESiA parent study

Exclusion Criteria:

  • Clinical atrial fibrillation documented by surface ECG (12 lead ECG, Telemetry, Holter) lasting ? 6 minutes, with or without clinical symptoms
  • Mechanical valve prosthesis, recent (within past 6 months) deep vein thrombosis or pulmonary embolism or other condition requiring treatment with an anticoagulant
  • Allergy to aspirin or apixaban
  • Severe renal insufficiency (serum creatinine > 2.5 mg/dL [221 ?mol/L] or a calculated creatinine clearance < 25 ml/min)
  • Serious bleeding in the last 6 months or at high risk of bleeding (this includes, but is not limited to: prior intracranial hemorrhage, active peptic ulcer disease, clinically significant thrombocytopenia or anemia, recent stroke within past 10 days, documented hemorrhagic tendencies or blood dyscrasias)
  • Moderate to severe hepatic impairment
  • Ongoing need for combination therapy with aspirin and clopidogrel (or other combination of two platelet inhibitors)
  • Meets criteria for requiring lower dose of apixaban AND also has ongoing need for strong inhibitors of both CYP3A4 and P-glycoprotein (e.g., ketoconazole, itraconazole, ritonavir or clarithromycin)
  • Ongoing need for strong inducers of both CYP3A4 and P-glycoprotein (e.g., rifampin, carbamazepine, phenytoin, St. John's wort)
  • Received an investigational drug in the past 30 days
  • Participants considered by the investigator to be unsuitable for the study for any of the following reasons:
  • Not agreeable for treatment with either aspirin or apixaban or anticipated to have poor compliance on study drug treatment
  • Unwilling to attend study follow-up visits
  • Life expectancy less than 2 years due to concomitant disease
  • Women who are pregnant, breast-feeding or of child-bearing potential without an acceptable form of contraception in place (sterilization, abstinence or other method with less than 1% failure rate)
Sex/Gender
Sexes Eligible for Study:All
Ages 55 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts
Contact: Malaika Mohammed, B.A.S613-696-7000 ext 10945[email protected]
Listed Location Countries Canada
Removed Location Countries  
 
Administrative Information
NCT Number NCT02840201
Other Study ID Numbers 20150023
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement
Plan to Share IPD:No
Responsible Party Peter Liu, Ottawa Heart Institute Research Corporation
Study Sponsor Ottawa Heart Institute Research Corporation
Collaborators
  • Population Health Research Institute
  • Genome Canada
  • Bristol-Myers Squibb
  • Pfizer
  • Medtronic
  • Canadian Institutes of Health Research (CIHR)
Investigators
Principal Investigator:Peter Liu, MDOttawa Heart Institute Research Corporation
PRS Account Ottawa Heart Institute Research Corporation
Verification Date May 2020